Transient Isolated, Idiopathic Growth Hormone Deficiency-A Self-Limiting Pediatric Disease with Male Predominance or a Diagnosis Based on Uncertain Criteria? Lesson from 20 Years' Real-World Experience with Retesting at One Center.
Joanna SmyczyńskaMaciej HilczerUrszula SmyczynskaAndrzej LewińskiRenata StawerskaPublished in: International journal of molecular sciences (2024)
In the majority of children with growth hormone (GH) deficiency (GHD), normal GH secretion may occur before the attainment of final height. The aim of the study was to assess the incidence of persistent and transient GHD and the effectiveness of recombined human GH (rhGH) therapy in children with isolated, idiopathic GHD with respect to the moment of therapy withdrawal and according to different diagnostic criteria of GHD. The analysis included 260 patients (173 boys, 87 girls) with isolated, idiopathic GHD who had completed rhGH therapy and who had been reassessed for GH and IGF-1 secretion. The incidence of transient GHD with respect to different pre- and post-treatment criteria was compared together with the assessment of GH therapy effectiveness. The incidence of transient GHD, even with respect to pediatric criteria, was very high. Normal GH secretion occurred before the attainment of near-final height. Application of more restricted criteria decreased the number of children diagnosed with GHD but not the incidence of transient GHD among them. Poor response to GH therapy was observed mainly in the patients with normal IGF-1 before treatment, suggesting that their diagnosis of GHD may have been a false positive. Further efforts should be made to avoid the overdiagnosis GHD and the overtreatment of patients.
Keyphrases
- growth hormone
- end stage renal disease
- risk factors
- randomized controlled trial
- ejection fraction
- newly diagnosed
- cerebral ischemia
- body mass index
- chronic kidney disease
- replacement therapy
- systematic review
- endothelial cells
- prognostic factors
- stem cells
- bone marrow
- cell therapy
- blood brain barrier
- mesenchymal stem cells
- binding protein
- quality improvement
- combination therapy